Table 4.
Treatment and outcomes
| PM | DM | CADM | |||
|---|---|---|---|---|---|
| ILD (N = 11) | No ILD (N = 12) | ILD (N = 11) | No ILD (N = 13) | ILD (N = 15) | |
| Initial immunosuppressive therapy | |||||
| Prednisone + Cyclosporine + Cyclophosphamide | 1 | 0 | 1 | 0 | 6 |
| Prednisone + Cyclosporine | 1 | 0 | 2 | 0 | 6 |
| Prednisone + Cyclophosphamide | 0 | 0 | 1 | 0 | 1 |
| Prednisone + Azathioprine | 1 | 3 | 1 | 2 | 0 |
| Prednisone + Tacrolimus | 0 | 0 | 1 | 0 | 0 |
| Prednisone + Methotrexate | 0 | 2 | 0 | 1 | 0 |
| Prednisone | 8 | 5 | 4 | 9 | 1 |
| No therapy | 0 | 2 | 1 | 1 | 1 |
| Treatment for maligancy | |||||
| Surgical resection | 0 | 1 | 1 | 4 | 0 |
| Chemotherapy | 0 | 2 | 1 | 4 | 0 |
| Outcome | |||||
| Death (number of patients) | 1 | 3 | 4 | 5 | 5 |
| Days from first visit to death | 267 | 1520 (1179–2125) | 376 (232–738) | 122 (32–1071) | 33 (27–41) |
| Cause of death | Renal failure | Aspiration pneumonia | ILD (2) | Aspiration pneumonia (3) | ILD (4) |
| Hypoglycemia | Breast cancer | Malignant lymphoma | Extradural hematoma | ||
| Sepsis | Brainstem infarction | lung cancer | |||
Initial immunosuppressive treatment and treatment for malignancies diagnosed simultaneously with the diagnoses of polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis or during the observation period and outcomes